Orexin-A is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Could complement circadian-regulating peptides like DSIP (sleep) for full sleep-wake cycle optimization. Proper stacking requires understanding each compound's mechanism and timing.
What Is Orexin-A Stacking?
Stacking means combining Orexin-A with one or more complementary peptides to potentially achieve synergistic effects. Because different peptides work through different mechanisms, strategic combinations can target multiple pathways simultaneously.
Orexin-A (Hypocretin-1) is a Neuropeptide hormone researched for increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation.
What Is the Best Orexin-A Stack?
Could complement circadian-regulating peptides like DSIP (sleep) for full sleep-wake cycle optimization.
This combination is popular because it targets multiple mechanisms without significant overlap in side-effect profiles.
How Does Orexin-A Stack With DSIP?
DSIP (Delta-Sleep-Inducing Peptide) is a Neuropeptide sleep modulator that works through Promotes slow-wave (delta) sleep by stimulating acetyltransferase activity through α1 adrenergic receptors. Modulates corticotropin-releasing factor (.
Combined with Orexin-A's effects on increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation, this stack covers improved sleep quality, increased slow-wave sleep, reduced sleep latency, stress reduction, improved sleep efficiency as well.
Typical stacking protocol: Orexin-A at not established for human peptide administration single dose in research protocols alongside DSIP at 100-300 mcg once daily in the evening. See our DSIP guide for details.
How Does Orexin-A Stack With CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog that works through CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, stimulating growth hormone synthesis and pulsatile secretion through the cAMP-PKA.
Combined with Orexin-A's effects on increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation, this stack covers increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects as well.
Typical stacking protocol: Orexin-A at not established for human peptide administration single dose in research protocols alongside CJC-1295 at 100-300 mcg 1-3 times daily, typically before bed. See our CJC-1295 guide for details.
How Does Orexin-A Stack With Ipamorelin?
Ipamorelin (Ipamorelin) is a Growth Hormone Secretagogue (GHS) / Ghrelin mimetic that works through Ipamorelin selectively stimulates GH release by mimicking ghrelin at the GHS-R receptor on pituitary somatotrophs. Unlike other GHRPs (GHRP-2, GHRP-6,.
Combined with Orexin-A's effects on increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation, this stack covers growth hormone release, improved sleep, fat loss, muscle recovery, bone density support as well.
Typical stacking protocol: Orexin-A at not established for human peptide administration single dose in research protocols alongside Ipamorelin at 200-300 mcg 2-3 times daily. See our Ipamorelin guide for details.
How Do You Time a Orexin-A Stack?
When stacking, timing each injection based on half-life is important. Orexin-A has a half-life of rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes, which influences when to administer relative to other compounds.
Some researchers inject all peptides at the same time; others stagger by 15-30 minutes. There's limited data on whether timing within the same session matters significantly.
What Should You NOT Stack With Orexin-A?
Avoid stacking peptides with similar mechanisms of action at full doses — this can lead to receptor desensitization without proportional benefit. Also avoid combining compounds where side-effect profiles overlap significantly.
When in doubt, introduce one new compound at a time to isolate its effects before building a full stack.
Calculate Your Orexin-A Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Orexin-A.
Open Calculator →Bottom Line on Orexin-A Stacking
Could complement circadian-regulating peptides like DSIP (sleep) for full sleep-wake cycle optimization. Start with a single compound, assess response, then add complements.
See our stacking and cycling guide for general principles.
Complete Guide
Orexin-A : Benefits, Dosage, Side Effects & Research
Related Reading
- Orexin-A Dosage Guide
- Orexin-A Benefits
- Orexin-A Side Effects
- Orexin-A Cycle Guide
- Orexin-A Research
- DSIP Complete Guide
Research-Grade Sourcing
If you're going to research Orexin-A, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Orexin-A?
Orexin-A (Hypocretin-1) is a Neuropeptide hormone. Naturally occurring peptide synthesized in the hypothalamus, regulating sleep-wake cycles and arousal. It is researched for increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation.
What is the recommended Orexin-A dosage?
Common dosages: not established for human peptide administration administered single dose in research protocols via intranasal (experimental human), intracerebroventricular (animal studies). Cycle length: single dose protocols; no established multi-week cycles. Half-life: rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of Orexin-A?
Limited human safety data. Potential increased heart rate and blood pressure. Poor blood-brain-barrier penetration limits peripheral dosing.
Is Orexin-A safe?
Orexin-A has shown a preliminary safety profile in research. Not FDA-approved. Research use only. Development focus has shifted to small molecule receptor agonists. All research should follow appropriate safety protocols.